NEW YORK, Feb 8 – Hyseq’s dwindling cash reserves notwithstanding, many investors and analysts expressed confidence that CEO George Rathmann would recruit the necessary financing to keep the company afloat.

The Sunnyvale, Calif.-based biopharmaceutical company said this morning that its reserves had dropped to just $2.7 million at the end of 2000, down from $30 million a year previously, and that Rathmann would extend a $20 million line of credit to help finance the company’s drug development efforts.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

A new report highlights the potential threats posed by advances in synthetic biology, NPR reports.

A Bloomberg reporter tried to get her genetic data deleted, but found it's not so simple to do.

Johns Hopkins University's Steven Salzberg and his colleagues have come up with a new estimate for the number of human genes, Nature News reports.

In Genome Research this week: study of intra-tumor heterogeneity, workflow resources for EPIGEN-Brazil, and more.